PROTOCOL NRG-GY018

Protocol Title:  “A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer” NCI Version Date: 07/3/2019

Attention Sites:

There were formatting issues with the NRG-GY018 protocol document that was posted on CTSU.org on 7/29/19. The document has now been fixed.

Anyone who downloaded NRG-GY018 (PVD 7/3/2019) before 8/2/19 should re-download the document with the "Post Date" of 02-Aug-2019 to assure they have the correctly formatted version.

Please note that there were no changes made to the protocol content.

 

Twitter
This message was sent to natasha-wilhelm@ouhsc.edu by NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Unsubscribe from all mailings Unsubscribe | Manage Subscription | Forward Email | Report Abuse


This is a Test Email only.
This message was sent for the sole purpose of testing a draft message.